Equities Analysts Offer Predictions for FBIO Q1 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO) – Research analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Fortress Biotech in a research report issued on Tuesday, March 11th. Roth Capital analyst J. Wittes expects that the biopharmaceutical company will earn $1.47 per share for the quarter. The consensus estimate for Fortress Biotech’s current full-year earnings is ($3.28) per share. Roth Capital also issued estimates for Fortress Biotech’s Q2 2025 earnings at $1.23 EPS, Q3 2025 earnings at $1.27 EPS and Q4 2025 earnings at $1.19 EPS.

Other equities research analysts have also issued research reports about the company. StockNews.com lowered Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Roth Mkm reissued a “buy” rating and set a $16.00 target price (up previously from $15.00) on shares of Fortress Biotech in a report on Tuesday. Finally, HC Wainwright boosted their price objective on Fortress Biotech from $24.00 to $26.00 and gave the company a “buy” rating in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, Fortress Biotech currently has a consensus rating of “Moderate Buy” and an average target price of $15.67.

Fortress Biotech Price Performance

Shares of FBIO stock opened at $1.73 on Wednesday. The stock’s fifty day moving average price is $1.79 and its 200 day moving average price is $1.80. Fortress Biotech has a 1-year low of $1.36 and a 1-year high of $2.89. The company has a market cap of $47.76 million, a price-to-earnings ratio of -0.57 and a beta of 1.75.

Hedge Funds Weigh In On Fortress Biotech

Large investors have recently made changes to their positions in the company. PVG Asset Management Corp increased its holdings in Fortress Biotech by 3.3% in the fourth quarter. PVG Asset Management Corp now owns 386,295 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 12,505 shares in the last quarter. Wolverine Trading LLC acquired a new stake in shares of Fortress Biotech during the 4th quarter valued at about $26,000. Two Sigma Investments LP purchased a new position in shares of Fortress Biotech in the 4th quarter valued at about $109,000. Jane Street Group LLC acquired a new position in Fortress Biotech in the 4th quarter worth about $69,000. Finally, Integrated Wealth Concepts LLC boosted its position in Fortress Biotech by 28.9% during the fourth quarter. Integrated Wealth Concepts LLC now owns 59,400 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 13,300 shares in the last quarter. 96.51% of the stock is currently owned by institutional investors and hedge funds.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.